The effect of omega-3 supplementation on blood cell indices, inflammatory markers, and immunoglobulins in patients with hidradenitis suppurativa

The effect of omega-3 supplementation on blood cell indices, inflammatory markers, and immunoglobulins in patients with hidradenitis suppurativa; A randomized, double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230123057193N8

Enrollment

Registered

2026-05-16

Start date

2026-01-05

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hidradenitis suppurativa. L73.2

Interventions

Intervention 1: Intervention group: Individuals in this group will receive two capsules containing 1000 mg of omega-3 (providing 120 mg DHA and 180 mg EPA) daily for 8 weeks. The omega-3 capsules will

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Aged 20 to 50 years Diagnosis of Hidradenitis Suppurativa Based on IHS4 Score and Hurley Staging (BMI) > 25 Disease severity according to Hurley stage I or II

Exclusion criteria

Exclusion criteria: Any history of alcohol consumption or tobacco use Currently breastfeeding, pregnant, or planning pregnancy within the next 3 months Use of corticosteroids, methotrexate, or anticoagulant medications Presence of chronic diseases such as cardiovascular disease, hypertension, diabetes mellitus, thyroid disorders, non-alcoholic fatty liver disease, or any diagnosed neoplasia/malignancy Use of antioxidant supplements or omega-3 supplements within the past 3 months

Design outcomes

Primary

Measure	Time frame
Interleukin-6. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Neutrophil-to-Lymphocyte Ratio (NLR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Platelet-to-Lymphocyte Ratio (PLR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;C-Reactive Protein (CRP). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Immunoglobulin A (IgA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Immunoglobulin G (IgG). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Complete Blood Count (CBC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measured using an automated analyzer.	—

Measure

Time frame

Interleukin-6. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Neutrophil-to-Lymphocyte Ratio (NLR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Platelet-to-Lymphocyte Ratio (PLR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;C-Reactive Protein (CRP). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Immunoglobulin A (IgA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Immunoglobulin G (IgG). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Complete Blood Count (CBC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measured using an automated analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSorayia Ebrahim pour koujan

Tehran University of Medical Sciences

nutri.seam1@gmail.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026